Comparison of cardiovascular disease risk assessment tools for heart failure prediction among cancer patients

30 August 2024 (09:00 - 09:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Thomas H Marwick

Baker Heart and Diabetes Institute, Melbourne (Australia)

7 More presentations in this session

Presentation thumbnail

ABO blood groups and platelet reactivity in patients with coronary artery disease undergoing percutaneous coronary intervention treated with clopidogrel

Mrs J. Li (Beijing, CN)

Abstract Slides Video

Presentation thumbnail

Ischemic and bleeding risk after ST-segment elevated myocardial infarction in patients with active cancer

Doctor M. Dafaalla (Stoke-on-Trent, GB)

Abstract Slides Video

Presentation thumbnail

External validation of the Systematic COronary Risk Evaluation 2 (SCORE2) model in cancer patients

Mrs M. Gynnild (Trondheim, NO)

Abstract Slides Video

Presentation thumbnail

Cancer-specific Heart Failure (HF) risk score - a new risk score developed specifically to predict HF among cancer survivors

Professor T. Marwick (Melbourne, AU)

Abstract Slides Video

Presentation thumbnail

Long-term prognostic impact of fasting plasma glucose and myocardial flow reserve beyond other risk factors and heart disease phenotypes

Doctor D. Neglia (Pisa, IT)

Abstract Slides Video

Access the full session

Session thumbnail

Cancer and other risk factors for heart disease

The Event

Event poster

ESC Congress 2024

30 August 2024 09:00 CET

You may be interested in

Congress Presentation

Cancer-specific Heart Failure (HF) risk score - a new risk score developed specifically to predict HF among cancer survivors

Congress Presentation

Predicting heart failure in cancer survivors: use of polygenic risk vs clinical score

Congress Presentation

Cancer survivorship - heart failure risk factor or potentiator?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources